Citation | Caldwell, RD; Qiu, H; Askew, BC; Bender, AT; Brugger, N; Camps, M; Dhanabal, M; Dutt, V; Eichhorn, T; Gardberg, AS; Goutopoulos, A; Grenningloh, R; Head, J; Healey, B; Hodous, BL; Huck, BR; Johnson, TL; Jones, C; Jones, RC; Mochalkin, I; Morandi, F; Nguyen, N; Meyring, M; Potnick, JR; Santos, DC; Schmidt, R; Sherer, B; Shutes, A; Urbahns, K; Follis, AV; Wegener, AA; Zimmerli, SC; Liu-Bujalski, L Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem62:7643-7655 (2019) [PubMed] Article |
---|
SMILES | Nc1ncnc(NCC2CCN(CC2)C(=O)C=C)c1-c1cc(F)c(Oc2ccccc2)cc1F |(-1.33,-6.93,;-2.67,-6.16,;-4,-6.93,;-5.33,-6.16,;-5.33,-4.62,;-4,-3.85,;-4,-2.31,;-5.33,-1.54,;-5.33,,;-4,.77,;-4,2.31,;-5.33,3.08,;-6.67,2.31,;-6.67,.77,;-5.33,4.62,;-4,5.39,;-6.67,5.39,;-6.67,6.93,;-2.67,-4.62,;-1.33,-3.85,;-1.33,-2.31,;,-1.54,;;1.33,-2.31,;2.67,-1.54,;4,-2.31,;4,-3.85,;5.33,-4.62,;6.67,-3.85,;6.67,-2.31,;5.33,-1.54,;1.33,-3.85,;,-4.62,;,-6.16,)| |